"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Descriptor ID |
D016219
|
MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 4 | 7 |
1995 | 7 | 2 | 9 |
1996 | 5 | 0 | 5 |
1997 | 4 | 2 | 6 |
1998 | 7 | 2 | 9 |
1999 | 2 | 1 | 3 |
2000 | 3 | 2 | 5 |
2001 | 6 | 2 | 8 |
2002 | 4 | 3 | 7 |
2003 | 6 | 8 | 14 |
2004 | 10 | 1 | 11 |
2005 | 7 | 1 | 8 |
2006 | 11 | 2 | 13 |
2007 | 8 | 2 | 10 |
2008 | 5 | 2 | 7 |
2009 | 6 | 3 | 9 |
2010 | 13 | 5 | 18 |
2011 | 20 | 2 | 22 |
2012 | 13 | 9 | 22 |
2013 | 9 | 6 | 15 |
2014 | 20 | 7 | 27 |
2015 | 15 | 2 | 17 |
2016 | 13 | 15 | 28 |
2017 | 21 | 8 | 29 |
2018 | 31 | 15 | 46 |
2019 | 30 | 10 | 40 |
2020 | 37 | 28 | 65 |
2021 | 51 | 25 | 76 |
2022 | 14 | 44 | 58 |
2023 | 16 | 54 | 70 |
2024 | 4 | 9 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication. Nat Commun. 2024 Mar 29; 15(1):2749.
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241.
-
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.
-
Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1152-1158.
-
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 Feb 29; 12(2).
-
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8(4):1042-1050.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024 Feb; 30(2):338-341.
-
Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024 May; 99(5):910-921.
-
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.